Chris Shibutani
Stock Analyst at Goldman Sachs
(3.55)
# 840
Out of 5,154 analysts
94
Total ratings
55.1%
Success rate
22.17%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $59.29 | +68.66% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $15.47 | -80.61% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $9.13 | +64.29% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.63 | +11.77% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $101.50 | +34.98% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $22.07 | +49.52% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $478.16 | -36.84% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $45.41 | +12.31% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $240.40 | -35.52% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $13.85 | -71.12% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $6.56 | +204.88% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $990.33 | -26.99% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $12.74 | +104.08% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $128.13 | +19.41% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $230.11 | -24.82% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.70 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $60.29 | +14.45% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $22.03 | -40.99% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $98.40 | -76.63% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $83.49 | -37.72% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $27.05 | +121.81% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $12.58 | +43.08% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $16.95 | +0.29% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.19 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.05 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $59.29
Upside: +68.66%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $15.47
Upside: -80.61%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $9.13
Upside: +64.29%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.63
Upside: +11.77%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $101.50
Upside: +34.98%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $22.07
Upside: +49.52%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $478.16
Upside: -36.84%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $45.41
Upside: +12.31%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $240.40
Upside: -35.52%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $13.85
Upside: -71.12%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $6.56
Upside: +204.88%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $990.33
Upside: -26.99%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $12.74
Upside: +104.08%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $128.13
Upside: +19.41%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $230.11
Upside: -24.82%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $70.70
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $60.29
Upside: +14.45%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $22.03
Upside: -40.99%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $98.40
Upside: -76.63%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $83.49
Upside: -37.72%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $27.05
Upside: +121.81%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $12.58
Upside: +43.08%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $16.95
Upside: +0.29%
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.19
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.05
Upside: -